Case Report
Chronic Lymphocytic Leukemia and Myelofibrosis
Table 1
Clinical characteristics of reported patients with CLL and PMF.
| | Report | Patient’s number | Age at CLL diagnosis, mean (years) | Sex, males/females (% males) | Time between CLL and PMF Dx, median (years) | Chemotherapy, n (%) | Simultaneous diagnosis of CLL and myelofibrosis, n (%) | Death after myelofibrosis diagnosis, n (%) | Survival, median (years) |
| | Lennard et al. [6] | 1 | 42 | 0/1 (0) | 6.3 | 1 (100) | 0 (0) | 1 (100) | 0.45 | | Nieto et al. [7] | 1 | 70 | 0/1 (0) | 2.3 | Not given | 0 (0) | Not available | Not available | | Palta et al. [8] | 1 | 60 | 1/0 (100) | 0 | Prednisolone | 1 (100) | Not available | Not available | | Burgstaller et al. [9] | 1 | 61 | 0/1 (0) | 0 | Lenalidomide | 1 (100) | No | Not available | | Laurenti et al. [11] | 4 | 69.75 | 4/0 (100) | Not available | 1 (25) | 2 (50) | Not available | Not available | | Salama et al. [14] | 2 | 68 | 2/0 (100) | 4.5 (0–9) | Hydroxyurea | 1 (50) | No | Not available | | Todisco et al. [15] | 8 | 60.3 | Not available | 6.05 (0–13.6) | 5 (62.5) | 1 (12.5) | 4 (50) | 8.9 (0.7–15.7) | | Marchetti et al. [16] | 23 | 66.5 (26–81) | Not available | 6 | Not available | 7 (30.4) | Not available | Not available |
|
|
